Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00564954 · ClinicalTrials.gov registry record · Phase 4

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 4 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
86
Enrollment target

NCT00564954: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.

NCT00564954 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00564954, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
86 participants
Enrollment target

Study Summary

This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.

Primary Outcome

SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.

Interventions

  • DRUG Placebo
  • DRUG Dex-methylphenidate hydrochloride extended-release (Focalin XR)

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2007-10
Est. Completion 2007-11
Phase Phase 4
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00564954 record still lists

NCT00564954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00564954 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00564954 about?

NCT00564954 is a clinical study titled "A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)". This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.

What is the current status of trial NCT00564954?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2007-10. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00564954?

The interventions under investigation include: Placebo (DRUG), Dex-methylphenidate hydrochloride extended-release (Focalin XR) (DRUG).

Who is sponsoring clinical trial NCT00564954?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00564954's enrollment target sits among peer trials

86 926th of 2000 higher than 1,073 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00564954, the US trial registry maintained by the National Library of Medicine. NCT00564954 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.